PMID- 35754338
OWN - NLM
STAT- MEDLINE
DCOM- 20221011
LR  - 20221021
IS  - 1477-0377 (Electronic)
IS  - 1358-863X (Linking)
VI  - 27
IP  - 5
DP  - 2022 Oct
TI  - Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A 
      systematic review and meta-analysis of randomized controlled trials.
PG  - 433-439
LID - 10.1177/1358863X221101653 [doi]
AB  - BACKGROUND: Arterial stiffness represents an established cardiovascular risk 
      marker. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have significant 
      cardio-protective effects. Herein we sought to determine the effect of SGLT-2 
      inhibitors on pulse wave velocity (PWV). METHODS: We searched PubMed, Cochrane 
      Library, and grey literature from inception to 7(th) February 2022 for randomized 
      controlled trials (RCTs) enrolling adult subjects with or without type 2 diabetes 
      mellitus (T2DM), assigned to a SGLT-2 inhibitor versus control and addressing 
      their effect on PWV. We set as primary efficacy outcome the change in PWV with 
      SGLT-2 inhibitors versus placebo or control. RESULTS: We pooled data from six 
      trials in a total of 452 enrolled participants assigned either to SGLT-2 
      inhibitor or control. Overall, SGLT-2 inhibitor treatment compared to control 
      resulted in a nonsignificant decrease in PWV. Exclusion of a trial utilizing 
      cardiac magnetic resonance imaging for the assessment of PWV demonstrated that 
      SGLT-2 inhibitors induce a significant reduction in PWV by 0.21 m/s. When we 
      restricted our analysis to RCTs enrolling subjects with T2DM, we observed that 
      SGLT-2 inhibitor compared to control resulted in a significant decrease in PWV by 
      0.17 m/s. CONCLUSION: SGLT-2 inhibitors do not decrease PWV in patients with 
      established cardiovascular disease or cardiovascular risk factors. However, we 
      have shown that SGLT-2 inhibitors lead to a slight, but significant decrease in 
      PWV in patients with T2DM. The latter finding is of great value, based on the 
      significant correlation between PWV and micro- and macro-vascular complications 
      of T2DM.
FAU - Patoulias, Dimitrios
AU  - Patoulias D
AUID- ORCID: 0000-0002-6899-684X
AD  - Second Propedeutic Department of Internal Medicine, Aristotle University of 
      Thessaloniki, General Hospital 'Hippokration', Thessaloniki, Greece.
FAU - Papadopoulos, Christodoulos
AU  - Papadopoulos C
AD  - Third Department of Cardiology, Aristotle University of Thessaloniki, General 
      Hospital 'Hippokration', Thessaloniki, Greece.
FAU - Kassimis, George
AU  - Kassimis G
AD  - Second Department of Cardiology, Aristotle University of Thessaloniki, General 
      Hospital 'Hippokration', Thessaloniki, Greece.
FAU - Fragakis, Nikolaos
AU  - Fragakis N
AD  - Third Department of Cardiology, Aristotle University of Thessaloniki, General 
      Hospital 'Hippokration', Thessaloniki, Greece.
FAU - Vassilikos, Vassilios
AU  - Vassilikos V
AD  - Third Department of Cardiology, Aristotle University of Thessaloniki, General 
      Hospital 'Hippokration', Thessaloniki, Greece.
FAU - Karagiannis, Asterios
AU  - Karagiannis A
AD  - Second Propedeutic Department of Internal Medicine, Aristotle University of 
      Thessaloniki, General Hospital 'Hippokration', Thessaloniki, Greece.
FAU - Doumas, Michael
AU  - Doumas M
AD  - Second Propedeutic Department of Internal Medicine, Aristotle University of 
      Thessaloniki, General Hospital 'Hippokration', Thessaloniki, Greece.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220627
PL  - England
TA  - Vasc Med
JT  - Vascular medicine (London, England)
JID - 9610930
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Adult
MH  - *Cardiovascular Diseases/diagnosis/prevention & control
MH  - *Diabetes Mellitus, Type 2/diagnosis/drug therapy
MH  - Humans
MH  - *Hypoglycemic Agents/adverse effects/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - *Sodium-Glucose Transporter 2 Inhibitors/adverse effects/therapeutic use
MH  - *Vascular Stiffness
OTO - NOTNLM
OT  - SGLT-2 inhibitors
OT  - arterial stiffness
OT  - cardiovascular disease
EDAT- 2022/06/28 06:00
MHDA- 2022/10/12 06:00
CRDT- 2022/06/27 03:13
PHST- 2022/06/28 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/06/27 03:13 [entrez]
AID - 10.1177/1358863X221101653 [doi]
PST - ppublish
SO  - Vasc Med. 2022 Oct;27(5):433-439. doi: 10.1177/1358863X221101653. Epub 2022 Jun 
      27.